Clinically, intravenous anti-CD20 mAb therapy typically induces a rapid decrease in circulating CLL cells (within hours), followed by a long period (days) of stable to increased levels of circulating cells. Similarly, our live cell time-lapse video assay shows initial rapid ADCP over the first ...
A representative example of the titration curve for patient 4 during rituximab therapy with the 1:5000 dilution indicated (black arrow) that lies within the linear phase of the dilution curve. (B) Each patient's Ab titer over the course of rituximab therapy was plotted at 1:5000 dilution. ...
Anti-CD20 therapy of ocular disordersdoi:CN1845755 A本申请描述了利用结合CD-20的拮抗剂诸如抗体的眼部疾病的治疗。 The present application describes the use of binding CD-20 antagonist treatment of eye diseases such as antibodies.保罗·G·布鲁尼塔...
Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells. 来自 掌桥科研 喜欢 0 阅读量: 47 作者:C Capuano,M Romanelli,C Pighi,G Cimino,R Galandrini 摘要: Natural killer (NK) immune cells mediate antibody-dependent cellular cytotoxicity (ADCC) by ...
Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. We have previously proposed the CD20 molecule as a novel suicide gene for T lymphocytes in the context of allogeneic bone marrow transplantation, because C...
A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic...
Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. Twelve patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma (B-NHL) were enrolled in a phase I study of rituximab; 4 received rituximab 250 mg/m 2 a....
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma Author links open overlay panelDavid G. Maloney, Antonio J. Grillo-López, Christine A. White, David Bodkin, Russell J. Schilder, James A. Neidhart, Nalini Janakiraman, ...
2.The method of claim 1, wherein the patient is a candidate for anti-CD20 therapy. 3.The method of claim 2, wherein the anti-CD20 therapy is rituximab. 4.The method of claim 1, wherein the expression of the genes is measured by measuring the level of RNA transcribed from each gene...
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular... Colombat,P. - 《Blood》 被引量: 1074发表: 2001年 IDEC-C2B8 (rituximab) anti-CD20 antibody therapy in patients with relapsed low-grad...